• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

ABBV STOCK HITS RECORD ALL TIME HIGH

Quote
anonymous said:
Humira sales down in Q2 with Mylan and Amgen ready to pounce on market share.
Fast track approval for Rova T turns into no approval.
Citron attaches a price target of $60.
Fda fast tracking generics to breech Humira patent proctection.
Metrics on whole pipeline tanking.
ROA for 2017 at lowest levels since 2014, returning 7.5% compared to a high of 9.7% in 2015. Working capital for 2017 saw its lowest level of 1.28. Now ROA for 2018 is looking even worse.

ALL this and Rick raises guidance?
Click to expand...

Hows that raised guidance working out Rick ?
AbbVie Inc
NYSE: ABBV
91.66 USD −0.94 (1.02%)
 




anonymous said:
This is being looked at very closely and related to Citron's "dirty money" accusation.
Big surprise on ER coming Friday. Another cat will be let out of the bag.
Click to expand...

So put two and two together and Richard benefited financially from the alleged illegal activity in California. Hmmm. In what other States was this going on? Informed individualals knew what citron meant by “dirty money” and the whistleblower or thier attorneys was in contact them and they leaked it. You should be paid for such great info on here months before it breaks.
They hate you in HQ. Keep up the good work.
 




anonymous said:
News Flash Humira Patent expires in Q418 in Europe. Rick claims only a 20% decline through Q419. and smaller declines thereafter. The real decline will be a whopping 30% off the $6B in sales as there are three biosimilars launching The Stock will NEVER see $123 again and massive RIFs and WARNs are going to be executed in 2020 2021. Better start looking now if you're smart.
Click to expand...

Humira legacy rep here, we all know it’s over within two years. Only a handful are leaving and most of them are retiring with large pension from Abbott days.
 
























anonymous said:
Humira sales down in Q2 with Mylan and Amgen ready to pounce on market share.
Fast track approval for Rova T turns into no approval.
Citron attaches a price target of $60.
Fda fast tracking generics to breech Humira patent proctection.
Metrics on whole pipeline tanking.
ROA for 2017 at lowest levels since 2014, returning 7.5% compared to a high of 9.7% in 2015. Working capital for 2017 saw its lowest level of 1.28. Now ROA for 2018 is looking even worse.

ALL this and Rick raises guidance?
Click to expand...



YIKES !!!! The house of cards is tumbling down. Looking for $70s soon.
JUMP SHIP NOW
AbbVie Inc
NYSE: ABBV
85.74 USD Down−2.23 (2.53%)
 
















My broker said if I buy ABBV, I’ll experience.........


clubber-lang-pain.jpg
 
















$82 and sinking. CFO bailing out at age 50 for mysterious reasons, multiple pipeline failures and I read Democrat-controlled House will be coming after drug pricing, including public hearings so no relief in sight. What is going on here? Not what I envisioned when I got my stock options at $90 or whatever it was...
 




anonymous said:
Not so fast genuises ! A few more adverse events or ANY negative results in trials of Rova-T, Elagoix, Upadacitinib, or Risankizumab combined with the clock ticking down on Humira could push this stock back to the $60s so fast your head will spin. Let's hope not, but smart investors won't EVER rule it out.
Click to expand...



AbbVie Inc
Oct 24, 3:20
NYSE: ABBV
79.89 USD −3.05 (3.68%)
th
 












Top Bottom
Back
Quote